15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications

[1]  A. Terano,et al.  A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide , 2006, Journal of gastroenterology and hepatology.

[2]  S. Chiou,et al.  Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. , 2005, Biochemical and biophysical research communications.

[3]  A. Tarnawski,et al.  Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence , 1996, Digestive Diseases and Sciences.

[4]  Y. Naito,et al.  Rebamipide protects against activation of neutrophils byHelicobacter pylori , 1996, Digestive Diseases and Sciences.

[5]  S. Kluge,et al.  Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats , 1993, Digestive Diseases and Sciences.

[6]  K. Tominaga,et al.  Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-α , 2004 .

[7]  H. Shinohara,et al.  Rebamipide Increases the Amount of Mucin-like Substances on the Conjunctiva and Cornea in the N-Acetylcysteine-Treated In Vivo Model , 2004, Cornea.

[8]  S. Chiou,et al.  Rebamipide Activates Genes Encoding Angiogenic Growth Factors and Cox2 and Stimulates Angiogenesis: A Key to Its Ulcer Healing Action? , 2004, Digestive Diseases and Sciences.

[9]  K. Tominaga,et al.  Rebamipide Prevents Delay of Acetic Acid-Induced Gastric Ulcer Healing Caused by Helicobacter pylori Infection in Mongolian Gerbils , 2002, Digestive Diseases and Sciences.

[10]  A. Keshavarzian,et al.  Modulatory Effects of Plasma and Colonic Milieu of Patients with Ulcerative Colitis on Neutrophil Reactive Oxygen Species Production in Presence of a Novel Antioxidant, Rebamipide , 2002, Digestive Diseases and Sciences.

[11]  K. Chayama,et al.  Long-Term Rebamipide Therapy Improves Helicobacter pylori-Associated Chronic Gastritis , 2002, Digestive Diseases and Sciences.

[12]  Shinya Kishimoto,et al.  Rebamipide, an Antiulcer Drug, Prevents DSS-Induced Colitis Formation in Rats , 2000, Digestive Diseases and Sciences.

[13]  Hyeyoung Kim,et al.  Inhibition of Lipid Peroxidation, NF-κB Activation and IL-8 Production by Rebamipide in Helicobacter pylori-Stimulated Gastric Epithelial Cells , 2000, Digestive Diseases and Sciences.

[14]  Y. Fujiwara,et al.  Inhibition by 16,16-Dimethyl Prostaglandin E2 of Tumor Necrosis Factor-α and Interleukin-1β Production and Messenger RNA Expression in Human Monocytes Stimulated by Helicobacter pylori , 1999, Digestive Diseases and Sciences.

[15]  H. Wakebe,et al.  Delayed Gastric Emptying by Helicobacter pylori Lipopolysaccharide in Conscious Rats , 2004, Digestive Diseases and Sciences.

[16]  K. Haruma,et al.  Review article: clinical significance of mucosal‐protective agents: acid, inflammation, carcinogenesis and rebamipide , 2003, Alimentary pharmacology & therapeutics.

[17]  E. Sasaki,et al.  Comparison of the effects of rebamipide with those of cimetidine on chronic gastritis associated with Helicobacter pylori in Mongolian gerbils , 2003, Alimentary pharmacology & therapeutics.

[18]  D. Kim,et al.  Effect of long‐term administration of rebamipide on Helicobacter pylori infection in mice , 2003, Alimentary pharmacology & therapeutics.

[19]  K. Tominaga,et al.  Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study , 2003, Alimentary pharmacology & therapeutics.

[20]  Y. Murawaki,et al.  Effect of Rebamipide on Acetic Acid-induced Gastric Ulcer in Rats: Involvement of Hepatocyte Growth Factor , 2003, Scandinavian journal of gastroenterology.

[21]  S. Ohno,et al.  Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease , 2003, Drugs in R&D.

[22]  Kazuhide Higuchi,et al.  Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. , 2002, Hepato-gastroenterology.

[23]  T. Fujishita,et al.  Effect of Rebamipide on Cell Death Induced by Combined Treatment of Mild Heat Shock and Quercetin in RGM-1 Cells: A Role for HSP70 Induction , 2001, Pharmacology.

[24]  A. Axon,et al.  Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. , 2001, Gastroenterology.

[25]  Ji Young Kim,et al.  The Inhibitory Mechanism of Rebamipide on the Mediator Release in the Guinea Pig Lung Mast Cells Activated with Specific Antigen-Antibody Reactions , 2001, Pharmacology.

[26]  W. Hong,et al.  The antioxidant effect of rebamipide on oxygen free radical production by H. pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic acid and glutathione. , 2001, Pharmacological research.

[27]  T. Azuma,et al.  Gastric leptin and Helicobacter pyloriinfection , 2001, Gut.

[28]  K. Tominaga,et al.  Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1β , 2001, Gut.

[29]  K. Sekiguchi,et al.  Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. , 2001, The Journal of pharmacology and experimental therapeutics.

[30]  G. Lindberg,et al.  Curing Helicobacter pylori Infection in Patients with Duodenal Ulcer Does Not Provoke Gastroesophageal Reflux Disease , 2000, Helicobacter.

[31]  A. Simjee,et al.  Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa , 2000, Alimentary pharmacology & therapeutics.

[32]  Y. Sasaki,et al.  Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. , 2000, The Journal of pharmacology and experimental therapeutics.

[33]  H. Seguchi,et al.  Suppressive effect of rebamipide, an antiulcer agent, against activation of human neutrophils exposed to formyl-methionyl-leucyl-phenylalanine. , 2000, Histology and histopathology.

[34]  K. Hong,et al.  Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappaB-dependent pathway. , 2000, The Journal of pharmacology and experimental therapeutics.

[35]  K. Lai,et al.  Ulcer‐healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage , 2000, Alimentary pharmacology & therapeutics.

[36]  F. Takeshima,et al.  Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. , 2000 .

[37]  S. Ishihara,et al.  Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. , 2000, The Journal of laboratory and clinical medicine.

[38]  T. A. Najjar,et al.  The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. , 2000, Pharmacological research.

[39]  F. Takeshima,et al.  Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative , 2000, American Journal of Gastroenterology.

[40]  F. Mégraud,et al.  Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis. , 2000, Scandinavian journal of gastroenterology.

[41]  K. Higuchi,et al.  Influence of Rebamipide on Indometacin-induced Gastric Hemorrhage in Rats under Restraint Stress , 1999, Arzneimittelforschung.

[42]  K. Matsushima,et al.  Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. , 1998, Digestive diseases and sciences.

[43]  Y. Fujiwara,et al.  Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. , 1998, Digestive diseases and sciences.

[44]  W. S. Lee,et al.  Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. , 1998, Digestive diseases and sciences.

[45]  A. Tarnawski,et al.  Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? , 1998, Digestive diseases and sciences.

[46]  K. Tominaga,et al.  Protective effect of rebamipide against ammonia-induced gastric mucosal lesions. , 1998, Digestive diseases and sciences.

[47]  A. Tarnawski,et al.  Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. , 1998, Digestive diseases and sciences.

[48]  H. Okabe,et al.  Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. , 1998, Digestive diseases and sciences.

[49]  Y. Naito,et al.  Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. , 1998, Digestive diseases and sciences.

[50]  Nobuhiro Fujii,et al.  Effect of Rebamipide, a Novel Antiulcer Agent, onHelicobacter pylori Adhesion to Gastric Epithelial Cells , 1998, Antimicrobial Agents and Chemotherapy.

[51]  A. Blum,et al.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. , 1997, Gastroenterology.

[52]  Toshio Watanabe,et al.  Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta. , 1997, The American journal of pathology.

[53]  K. Higuchi,et al.  Quality of ulcer healing influences the relapse of gastric ulcers in humans , 1997, Journal of gastroenterology and hepatology.

[54]  Y. Naito,et al.  Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. , 1995, Free radical biology & medicine.

[55]  Y. Naito,et al.  Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. , 1993, Arzneimittel-Forschung.

[56]  S. Takayama,et al.  Levofloxacin, a new quinolone antibacterial agent. An introductory overview. , 1992, Arzneimittel-Forschung.